Jan van de Winkel

Full Professor

Strategic program(s):

Contact

jwinkel4@umcutrecht.nl

Pure profile

Recent publications

All publications

Complement is activated by IgG hexamers assembled at the cell surface. C.A. Diebolder, F.J.M. Beurskens, R.N. de Jong, R.I. Koning, K. Strumane, M.A. Lindorfer, M.M. Voorhorst, D. Ugurlar, S Rosati, A.J.R. Heck, J.G.J. van de Winkel, I.A. Wilson, A.J. Koster, R.P. Taylor, E.O. Saphire, D.R. Burton, J. Schuurman, P. Gros, P.W.H.I. Parren
Science, 2014, vol. 343, p.1260-1263

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. A.F. Labrijn, J. Meesters, B.E. Goeij, E.T.J. van den Bremer, J. Neijssen, M.D. van Kampen, K. Strumane, S. Verploegen, A. Kundu, M.J. Gramer, P.H.C. van Berkel, J.G.J. van de Winkel, J. Schuurman, P.W.H.I. Parren
Proceedings of the National Academy of Sciences of the United States of America, 2013, vol. 110, p.5145-5150

IgA EGFR antibodies mediate tumour killing in vivo. P. Boross, S. Lohse, M. Nederend, J.H.M. Jansen, G. van Tetering, M. Dechant, M. Peipp, L. Royle, L.P. Liew, L Boon, N. van Rooijen, W.K. Bleeker, P. Parren, J.G.J. van de Winkel, T. Valerius, J.H.W. Leusen
Embo Molecular Medicine, 2013, vol. 5, p.1213-1216

The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells. P. Glorius, A. Baerenwaldt, C. Kellner, M. Staudinger, M. Dechant, M. Stauch, F.J. Beurskens, P.W.H.I. Parren, J.G.J. van de Winkel, T. Valerius, A. Humpe, R. Repp, M. Gramatzki, F. Nimmerjahn, M. Peipp
Leukemia, 2013, vol. 27, p.190-201

Staphylococcus aureus formyl peptide receptor-like 1 inhibitor (FLIPr) and its homologue FLIPr-like are potent FcγR antagonists that inhibit IgG-mediated effector functions A.M. Stemerding, J. Kohl, M.K. Pandey, A. Kuipers, J.H.W. Leusen, P. Boross, M. Nederend, G. Vidarsson, A.J.L. Weersink, J.G.J. van de Winkel, C.P.M. van Kessel, J.A.G. van Strijp
Journal of Immunology, 2013, vol. 191, p.353-362

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. C. Kellner, D. Hallack, P. Glorius, M. Staudinger, S. Mohseni Nodehi, M. de Weers, J.G.J. van de Winkel, P.W.H.I. Parren, M. Stauch, T. Valerius, R. Repp, A. Humpe, M. Gramatzki, M. Peipp
Leukemia, 2012, vol. 26, p.830-834